Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Kawai, Kosuke ^a   de Araujo, Gabriela Tannus B ^b   Fonseca, Marcelo ^b,c   Pillsbury, Matthew ^d   Singhal, Puneet K ^e  

^a TEMPLE UNIVERSITY   (United States)

^b AxiaBio Consulting   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Atlas Data Systems   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; BRAZIL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH ECONOMICS; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; MATHEMATICAL MODEL; QUALITY ADJUSTED LIFE YEAR; TRANSMISSION DYNAMIC MODEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

ADOLESCENT; ADULT; AGED; BRAZIL; CHILD; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84867136117     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-250     Document Type: Article

References (42)

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22(12):2675-2686. 10.1093/annonc/mdr015, 21471563.
2. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(3):3/1-10.
3. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278. 10.1016/S1470-2045(05)70101-7, 15863374.
4. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493. 2907480, 20647284.
5. Perez G, Lazcano-Ponce E, Hernandez-Avila M, Garcia PJ, Munoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008, 122(6):1311-1318.
6. Brazilian National Cancer Institute (Instituto Nacional De Cancer) Available at http://www2.inca.gov.br, Brazilian National Cancer Institute (Instituto Nacional De Cancer).
7. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MK, Xavier Bosch F, de Sanjose S, Franco EL. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25(33):6257-6270. 10.1016/j.vaccine.2007.05.058, 17606315.
8. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97(9):1322-1328. 10.1038/sj.bjc.6604023, 2360471, 17923869.
9. Colantonio L, Gomez JA, Demarteau N, Standaert B, Pichon-Riviere A, Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009, 27(40):5519-5529. 10.1016/j.vaccine.2009.06.097, 19616499.
10. Vanni T, Mendes Luz P, Foss A, Mesa-Frias M, Legood R. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine 2012, 30(32):4866-4871. 10.1016/j.vaccine.2012.04.087, 22652405.
11. Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 2011, 9:54. 10.1186/1741-7015-9-54, 3123559, 21569406.
12. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28(42):6858-6867. 10.1016/j.vaccine.2010.08.030, 20713101.
13. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41. 10.3201/eid1301.060438, 2725801, 17370513.
14. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009, 9:119. 10.1186/1471-2334-9-119, 2728100, 19640281.
15. United Nations Department of Economic and Social Affairs Population Division World Population Prospects: The 2010 Revision, UN 2011, Available in http://esa.un.org/unpd/wpp/Excel-Data/population.htm, United Nations Department of Economic and Social Affairs Population Division.
16. World Health Statistics Health statistics and health information systems. World Health Organization 2011, Available in http://www.who.int/healthinfo/statistics/mortality_life_tables/en/index.html, World Health Statistics.
17. Barbosa RM, Koyama MA. Sexual behavior and practices among men and women, Brazil 1998 and 2005. Rev Saude Publica 2008, 42(1):21-33.
18. de Quadros CA, Victora CG, da Costa JS. Coverage and focus of a cervical cancer prevention program in southern Brazil. Rev Panam Salud Publica 2004, 16(4):223-232.
19. Albuquerque KM, Frias PG, Andrade CL, Aquino EM, Menezes G, Szwarcwald CL. Pap smear coverage and factors associated with non-participation in cervical cancer screening: an analysis of the Cervical Cancer Prevention Program in Pernambuco State, Brazil. Cad Saude Publica 2009, 25(2):301-309.
20. Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jeronimo J, Lazcano-Ponce E. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008, 26(Suppl 11):L37-L48.
21. Flores-Luna L, Salazar-Martinez E, Escudero-De los Rios P, Gonzalez-Lira G, Zamora-Munoz S, Lazcano-Ponce E. Prognostic factors related to cervical cancer survival in Mexican women. Int J Gynaecol Obstet 2001, 75(1):33-42. 10.1016/S0020-7292(01)00471-4, 11597617.
22. Brazil Ministry of Health Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS (SIGTAP) Available in http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp, Brazil Ministry of Health.
23. Azevedo E Silva G, Girianelli VR, Gamarra CJ, . Bustamante-Teixeira MT Cervical cancer mortality trends in Brazil, 1981-2006. Cad Saude Publica 2010, 26(12):2399-2407. 10.1590/S0102-311X2010001200018, 21243234, Bustamante-Teixeira MT.
24. WHO/ICO Information Centre on HPV and Cervical Cancer HPV and cervical cancer in the 2007 report. Vaccine 2007, 25(3):1-230. WHO/ICO Information Centre on HPV and Cervical Cancer.
25. Brazil Ministry of Health Ministério da Saúde: Programa Nacional de DST e Aids. Prevalências e frequências relativas de Doenças Sexualmente Transmissíveis (DST) em populações selecionadas de seis capitais brasileiras 2008, Ministério da Saúde, Brasília, Available in http://bvsms.saude.gov.br/php/index.php, Brazil Ministry of Health.
26. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros M. Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region. Vaccine 2008, 26(Suppl 11):L1-L15.
27. d'Ottaviano-Morelli MG, Zeferino L, Cecatti JG, Terrabuio DR, Martinez EZ. Prevalence of cervical intraepithelial neoplasia and invasive carcinoma based on cytological screening in the region of Campinas, Sao Paulo, Brazil. Cad Saude Publica 2004, 20(1):153-159. 10.1590/S0102-311X2004000100031, 15029316.
28. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003, 36(11):1397-1403. 10.1086/375074, 12766834.
29. Scarbrough Lefebvre CD, Van Kriekinge G, Goncalves MA, de Sanjose S. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health 2011, 125(7):464-475. 10.1016/j.puhe.2011.01.016, 21722930.
30. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and cost of care in England. Sex Transm Infect 2011, 87(6):464-468. 10.1136/sti.2010.048421, 3253068, 21813567.
31. Macroeconomics and health: investing in health for economic development Report of the Commission on Macroeconomics and Health 2001, World Health Organization, Geneva.
32. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547. 10.1136/sextrans-2011-050234, 21970896.
33. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44. 10.1016/S1473-3099(10)70225-5, 21067976.
34. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006, 28:88-100. 10.1093/epirev/mxj006, 16740585.
35. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12(5-6):343-351.
36. Koleva D, De Compadri P, Padula A, Garattini L. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med 2011, 6(2):163-174. 10.1007/s11739-011-0529-3, 21312004.
37. Mortensen GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Public Health 2010, 10:113. 10.1186/1471-2458-10-113, 2848198, 20205944.
38. Vanni T, Legood R, Franco EL, Villa LL, Luz PM, Schwartsmann G. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer 2011, 129(3):671-679. 10.1002/ijc.25708, 20886598.
39. Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 2012, 30(2):425-435. 10.1016/j.vaccine.2011.10.067, 22075091.
40. Vaccine-preventable diseases: monitoring system - 2010 global summary. World Health Organization 2010, Available at http://www.who.int/immunization_monitoring/data/en/.
41. Malagón TDM, Boily M, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789. 10.1016/S1473-3099(12)70187-1, 22920953.
42. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(46):8443-8450. 10.1016/j.vaccine.2011.07.096, 21816193.